1. Home
  2. NVS
  3. NVS News

Latest Novartis AG (NVS) News on October 9, 2025

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains
NVS

Simply Wall St.

14 hours ago

Novartis (SWX:NOVN): Evaluating Fair Value as Investor Optimism Drives Recent Gains

Top Stock Reports for SAP, Novartis & Philip Morris
NVS

Zacks

a day ago

Top Stock Reports for SAP, Novartis & Philip Morris

Should You Buy Novartis Stock Before October 28?
NVS

Barchart

a day ago

Should You Buy Novartis Stock Before October 28?

Here's Why Novartis (NVS) is a Strong Value Stock
NVS

Zacks

a day ago

Here's Why Novartis (NVS) is a Strong Value Stock

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
NVS

Zacks

a day ago

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?
NVS

Simply Wall St.

2 days ago

Is There Still Room for Growth in Novartis Shares After Year-to-Date Rally?

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes
NVS

PR Newswire

2 days ago

Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care
NVS

PR Newswire

2 days ago

Rare Disease Therapeutics Market to Surpass US$ 495.27 Billion by 2033 as Gene Therapy, RNA-based Drugs, and Biologics Transform Patient Care

HS Connect Makes History with Times Square’s First Patient-Led Runway Show
NVS

Business Wire

2 days ago

HS Connect Makes History with Times Square’s First Patient-Led Runway Show

NVS

MT Newswires

2 days ago

Jade Biosciences Unveils JADE201 Antibody to Potentially Treat Autoimmune Diseases

3 Reasons Growth Investors Will Love Novartis (NVS)
NVS

Zacks

3 days ago

3 Reasons Growth Investors Will Love Novartis (NVS)

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth
NVS

PR Newswire

3 days ago

Luckie Names Scott Gelber Chief Executive Officer to Lead Next Phase of Agency's Growth

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
NVS

Zacks

3 days ago

Why Novartis (NVS) is a Top Momentum Stock for the Long-Term

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NVS

Zacks

3 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

2 Surefire Dividend Stocks to Buy for the Long Haul
NVS

Motley Fool

5 days ago

2 Surefire Dividend Stocks to Buy for the Long Haul

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
NVS

Zacks

6 days ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?
NVS

Zacks

7 days ago

Novartis AG (NVS) Hit a 52 Week High, Can the Run Continue?

NVS

MT Newswires

7 days ago

Kinaxis to Deploy Maestro Platform for Sweden's Sobi to Boost Rare Disease Supply Chains

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff
NVS

Investor's Business Daily

8 days ago

Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff

Pfizer Stock, Other Drugmakers Rally Again
NVS

The Wall Street Journal

8 days ago

Pfizer Stock, Other Drugmakers Rally Again

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
NVS

Zacks

8 days ago

Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi
NVS

GlobeNewswire

8 days ago

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

NCCN Awards Funding to Improve Care for People with Breast Cancer
NVS

PR Newswire

8 days ago

NCCN Awards Funding to Improve Care for People with Breast Cancer

NVS

MT Newswires

8 days ago

Immatics Names Venkat Ramanan CFO

Immatics Appoints Venkat Ramanan as Chief Financial Officer
NVS

GlobeNewswire

8 days ago

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals
NVS

GlobeNewswire

8 days ago

Iron Overload Syndrome Market Report 2025-2035, Profiles of Chiesi Group, Novartis, PHARMACOSMOS, Protagonist Therapeutics, Regeneron Pharmaceuticals

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site
NVS

The Wall Street Journal

9 days ago

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

NVS

MT Newswires

9 days ago

Novartis Receives FDA Approval for Skin Condition Treatment

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
NVS

PR Newswire

9 days ago

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

Amanda Nolen joins Totara as Non-Executive Director
NVS

PR Newswire

9 days ago

Amanda Nolen joins Totara as Non-Executive Director

Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol
NVS

PR Newswire

10 days ago

Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol

Pharma's Direct-To-Patient Wave Hits Novartis Next
NVS

Benzinga

10 days ago

Pharma's Direct-To-Patient Wave Hits Novartis Next

dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management
NVS

ACCESS Newswire

10 days ago

dHealth Intelligence Launches Revolutionary AI Agent That Transforms Personal Healthcare Management

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.
NVS

The Wall Street Journal

10 days ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx in U.S.

NVS

MT Newswires

10 days ago

Novartis to Launch US Direct-to-Patient Platform for Cosentyx

NVS

MT Newswires

10 days ago

Novartis Unit Begins Tender Offer to Acquire Tourmaline Bio

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
NVS

GlobeNewswire

10 days ago

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

Novartis announces commencement of tender offer to acquire Tourmaline Bio
NVS

GlobeNewswire

10 days ago

Novartis announces commencement of tender offer to acquire Tourmaline Bio

Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona
NVS

Insider Monkey

11 days ago

Novartis AG (NVS) To Present New Data on Kesimpta at ECTRIMS 2025 in Barcelona

NVS

Morningstar Research

13 days ago

Analyst Report: Novartis AG

Big Pharma Unfazed by Trump Tariffs, but Small Biotechs Face Vulnerability
NVS

The Wall Street Journal

13 days ago

Big Pharma Unfazed by Trump Tariffs, but Small Biotechs Face Vulnerability

Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs
NVS

The Wall Street Journal

13 days ago

Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs

NVS

MT Newswires

13 days ago

Amneal Pharmaceuticals Files Biologics License Application for Xolair Biosimilar

NVS

MT Newswires

13 days ago

Novartis Says Won't be Impacted by 100% Tariff on Branded Pharmaceutical Products

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
NVS

GlobeNewswire

13 days ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Is pharma’s IRA pricing battle running out of steam?
NVS

Pharma Voice

14 days ago

Is pharma’s IRA pricing battle running out of steam?

Trump Plans New Tariff Push With 100% Rate on Patented Drugs
NVS

Bloomberg

14 days ago

Trump Plans New Tariff Push With 100% Rate on Patented Drugs

Roche, Novartis underline U.S. plans after Trump pharma tariff announcement
NVS

Reuters

14 days ago

Roche, Novartis underline U.S. plans after Trump pharma tariff announcement

European pharma shares drop after Trump threatens more tariffs
NVS

Reuters

14 days ago

European pharma shares drop after Trump threatens more tariffs

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025
NVS

GlobeNewswire

14 days ago

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim
NVS

GlobeNewswire

14 days ago

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
NVS

GlobeNewswire

14 days ago

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Humana Extends TailorCare Tie-Up to Enhance MA Member Health
NVS

Zacks

15 days ago

Humana Extends TailorCare Tie-Up to Enhance MA Member Health

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL
NVS

Zacks

15 days ago

BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
NVS

GlobeNewswire

15 days ago

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations

Novartis (SWX:NOVN): Evaluating Current Valuation During a Period of Market Caution
NVS

Simply Wall St.

15 days ago

Novartis (SWX:NOVN): Evaluating Current Valuation During a Period of Market Caution

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
NVS

GlobeNewswire

16 days ago

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

MLAB Biosciences Expands Scientific Advisory Board with Appointments of Peter Kang and Kathryn Wagner, Deepening Scientific Expertise in Neuromuscular Medicine
NVS

PR Newswire

16 days ago

MLAB Biosciences Expands Scientific Advisory Board with Appointments of Peter Kang and Kathryn Wagner, Deepening Scientific Expertise in Neuromuscular Medicine

Roche CEO, pharma execs to meet with Swiss government over US tariffs
NVS

Reuters

17 days ago

Roche CEO, pharma execs to meet with Swiss government over US tariffs

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors
NVS

Business Wire

17 days ago

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Novartis chief eyes ways to end higher US drug prices: media
NVS

AFP

19 days ago

Novartis chief eyes ways to end higher US drug prices: media

Novartis has stockpiles to withstand potential Trump tariffs, CEO says
NVS

Reuters

19 days ago

Novartis has stockpiles to withstand potential Trump tariffs, CEO says

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
NVS

Zacks

20 days ago

INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
NVS

Zacks

21 days ago

RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline

Why Novartis (NVS) is a Top Value Stock for the Long-Term
NVS

Zacks

21 days ago

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
NVS

Zacks

22 days ago

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

INCY Announces New Late-Stage Data on Skin Disease Drug
NVS

Zacks

22 days ago

INCY Announces New Late-Stage Data on Skin Disease Drug

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis
NVS

Zacks

23 days ago

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
NVS

Zacks

23 days ago

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?

Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?
NVS

Simply Wall St.

23 days ago

Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?

Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline
NVS

GlobeNewswire

23 days ago

Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline

Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
NVS

Pharmaceutical Technology

24 days ago

Novartis returns to Monte Rosa for second time in a year with $5.7bn deal

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal
NVS

GuruFocus.com

24 days ago

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition
NVS

Insider Monkey

24 days ago

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

NVS

MT Newswires

24 days ago

Traders Cautious Ahead of Fed Meeting, Driving Muted Premarket Action for US Equity Futures

NVS

The Bergen Record

24 days ago

3 firms to lay off hundreds of North Jersey-based employees

NVS

Investing.com

24 days ago

Monte Rosa surges premarket on Novartis collaboration deal

NVS

MT Newswires

24 days ago

Top Premarket Gainers

NVS

MT Newswires

24 days ago

Monte Rosa Therapeutics Partners With Novartis on Immune Disease Degraders; Shares Rise Pre-Bell

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics
NVS

Reuters

24 days ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
NVS

GlobeNewswire

24 days ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls
NVS

The Fly

a month ago

Molson Coors downgraded, GM upgraded: Wall Street's top analyst calls

More leaders are recognizing the ‘power of small teams’
NVS

Fortune

a month ago

More leaders are recognizing the ‘power of small teams’

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
NVS

Zacks

a month ago

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's
NVS

Simply Wall St.

a month ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

Top 20 biopharma market caps fall 5.7% amid industry challenges
NVS

Pharmaceutical Technology

a month ago

Top 20 biopharma market caps fall 5.7% amid industry challenges

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
NVS

Zacks

a month ago

5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
NVS

Zacks

a month ago

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More
NVS

GlobeNewswire

a month ago

Chronic Myelomonocytic Leukemia Market Analysis and Forecast Report 2025-2035, with Profiles of AbbVie, GlaxoSmithKline, Incyte, Jazz Pharmaceuticals, Novartis, Stemline Therapeutics, and More

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.
NVS

Pharma Voice

a month ago

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)
NVS

Insider Monkey

a month ago

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal
NVS

GuruFocus.com

a month ago

Novartis to Acquire Tourmaline Bio in $1.4 Billion Deal

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
NVS

Investor's Business Daily

a month ago

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'

NVS

MT Newswires

a month ago

Sector Update: Health Care Stocks Advance Late Afternoon

NVS

MT Newswires

a month ago

Sector Update: Health Care

NVS

MT Newswires

a month ago

Top Midday Gainers

3 firms to lay off hundreds of North Jersey-based employees
NVS

The Bergen Record

a month ago

3 firms to lay off hundreds of North Jersey-based employees

NVS

MT Newswires

a month ago

Tourmaline Bio Agrees to $1.4 Billion Takeover by Novartis

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal
NVS

The Wall Street Journal

a month ago

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

Novartis to acquire Tourmaline Bio for $1.4 billion
NVS

Reuters

a month ago

Novartis to acquire Tourmaline Bio for $1.4 billion

Share on Social Networks: